Indian pharmaceutical major, Sun Pharmaceutical Industries, has declared a profit after tax of Rs 2,047 crore for the quarter ended in September, increasing by 12.9 percent compared to Rs 1,813 crore reported in the same quarter in 2020. Strong operating performance and healthy revenue growth supported bottomline during the quarter.
Consolidated revenue came in higher at Rs 9,626 crore for the quarter, compared to Rs 8,553 crore in September 2020 quarter, registering a 12.5 percent growth.
The sequential growth in profit and revenue was 41.8 percent and (-1) percent respectively.
Broadly numbers were better than analysts' expectations. Profit was estimated at Rs 1,567.6 crore on revenue of Rs 8,980.3 crore, according to the average of estimates of analysts polled by CNBC-TV18.
The operating performance was also good and higher than expectations. EBITDA (earnings before interest, tax, depreciation and amortisation) grew by 19.9 percent year-on-year to Rs 2,630 crore and margin expanded by 170 bps to 27.3 percent in the quarter ended September 2022, beating CNBC-TV18 poll estimates which were pegged at Rs 2,219.7 crore and 24.7 percent respectively for the quarter.
To Know All Earnings Related News, Click Here
The stock rallied 2.11 percent to trade at Rs 829.50 on the BSE at 14:07 hours IST. During the last one year the stock has moved up by 74 percent and by 37 percent in this financial year. The stock is up 5 percent in the past three month but down 2 percent in the past one month.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
